Mainz Biomed B.V.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product ca…
Medical - Diagnostics & Research
DE, Mainz [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Mainz Biomed B.V.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2022 | -1.6700 | -1.840 | 0.58 | 0.57 | -12 | -29 | -9 | 0.51 | -9 | 0.55 | 9 | 9 |
| 2023 | -1.8700 | -1.690 | 0.53 | 0.94 | -26 | -27 | -25 | 0.85 | -26 | 0.91 | 22 | 15 |
| 2024 | -1.6200 | -0.640 | 0.90 | 2 | -26 | -10 | -24 | -1 | -26 | -1 | 17 | 32 |
| 2025 | - | -0.530 | - | 6 | - | -8 | - | -5 | - | -6 | - | 102 |
| 2026 | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F41/td> | - | 2.F41 | - | 2.F41 |
| 2027 | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F51/td> | - | 1.F51 | - | 1.F51 |
| 2028 | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F61/td> | - | 0.F61 | - | 0.F61 |